CSNK2A1 and osteosarcoma: Under doxorubicin treatment of U2OS and KHOS/NP osteosarcoma cells, the expression levels of cleaved PARP1, cleaved caspase 3, and BAX increased, and the expression of BCL2 decreased with the knock-down of CSNK2A1 (Figure 4).